Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection

El-Haddad, Amer MD
Erlich, Deborah MD, MMedEd, FAAFP

Tufts University School of Medicine, Boston, Massachusetts

Author disclosure: No relevant financial relationships.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

American Family Physician 107(5):p 545-546, May 2023.

Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1) antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, the most common form of HIV.